Featured Research

from universities, journals, and other organizations

Anti-anginal Drug Safe But Not Effective In Reducing Major Cardiac Events In ACS Patients

Date:
April 26, 2007
Source:
JAMA and Archives Journals
Summary:
The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.

The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.

Despite advances in the treatment of acute coronary syndromes (ACS), the risk of recurrent events remains substantial. The medication ranolazine is used for patients with chronic angina, but because of an association between ranolazine and prolongation of the QT interval (a certain measurement on an electrocardiogram), there is a need for additional safety information to guide its use in patients with coronary artery disease. The effectiveness and safety of the drug had not previously been studied in patients with ACS or for secondary prevention of major cardiovascular events in patients with established coronary artery disease, according to background information in the article.

David A. Morrow, M.D., M.P.H., of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues with the MERLIN (Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndromes)-TIMI 36 trial evaluated the efficacy and safety of ranolazine as a new treatment to reduce cardiovascular death, heart attack or recurrent ischemia in moderate- to high-risk patients with non--ST-elevation (a certain pattern on an electrocardiogram) ACS. The randomized, multinational clinical trial included 6,560 patients who within 48 hours of ischemic symptoms were treated with ranolazine (initiated intravenously and followed by oral ranolazine extended-release 1,000 mg twice daily, n = 3,279) or matching placebo (n = 3,281), and followed up for a midpoint of 348 days.

The primary end point (cardiovascular death, heart attack, or recurrent ischemia) occurred in 21.8 percent of the patients in the ranolazine group, compared with 23.5 percent of the patients in the placebo group. The major secondary end point (cardiovascular death, heart attack, or severe recurrent ischemia) occurred in 18.7 percent of the patients in the ranolazine group compared with 19.2 percent of the patients in the placebo group. Failure of therapy (including cardiovascular death, heart attack, recurrent ischemia, hospitalization for new or worsening heart failure) occurred at similar rates in both groups. The risk of recurrent ischemia was reduced in the ranolazine group (13.9 percent) compared with the placebo group (16.1 percent). Symptomatic documented arrhythmias did not differ between the two groups. There was little difference in the total number of deaths between the ranolazine and placebo groups (172 vs. 175, respectively).

"The results of this robustly powered, randomized trial do not support the use of ranolazine for acute management of ACS or as disease-modifying therapy for secondary prevention of cardiovascular death or [heart attack]. However, our findings suggest a benefit of ranolazine as antianginal therapy in a substantially more broad population of patients with established ischemic heart disease than previously studied," the authors write. "These findings, together with the observed favorable overall profile of safety, provide additional evidence to guide the use of ranolazine as antianginal therapy in patients with chronic angina."

(JAMA. 2007;297:1775-1783.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Anti-anginal Drug Safe But Not Effective In Reducing Major Cardiac Events In ACS Patients." ScienceDaily. ScienceDaily, 26 April 2007. <www.sciencedaily.com/releases/2007/04/070424180936.htm>.
JAMA and Archives Journals. (2007, April 26). Anti-anginal Drug Safe But Not Effective In Reducing Major Cardiac Events In ACS Patients. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2007/04/070424180936.htm
JAMA and Archives Journals. "Anti-anginal Drug Safe But Not Effective In Reducing Major Cardiac Events In ACS Patients." ScienceDaily. www.sciencedaily.com/releases/2007/04/070424180936.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins